Becton Dickinson and Co (BDX) : Cutler Investment Counsel scooped up 138 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 44,614 shares of Becton Dickinson and Co which is valued at $7.4 Million.Becton Dickinson and Co makes up approximately 2.26% of Cutler Investment Counsel’s portfolio.
Other Hedge Funds, Including , Shinko Asset Management Ltd. reduced its stake in BDX by selling 63 shares or 10.26% in the most recent quarter. The Hedge Fund company now holds 551 shares of BDX which is valued at $91,626. Hugh Johnson Advisors added BDX to its portfolio by purchasing 1,328 company shares during the most recent quarter which is valued at $220,833. Becton Dickinson and Co makes up approx 0.09% of Hugh Johnson Advisors’s portfolio. Ausdal Financial Partners sold out all of its stake in BDX during the most recent quarter. The investment firm sold 125 shares of BDX which is valued $20,605. Arcus Capital Partners sold out all of its stake in BDX during the most recent quarter. The investment firm sold 8 shares of BDX which is valued $1,319.Gamble Jones Investment Counsel reduced its stake in BDX by selling 167 shares or 1.1% in the most recent quarter. The Hedge Fund company now holds 15,058 shares of BDX which is valued at $2.5 Million. Becton Dickinson and Co makes up approx 0.28% of Gamble Jones Investment Counsel’s portfolio.
Becton Dickinson and Co opened for trading at $166.29 and hit $168.86 on the upside on Monday, eventually ending the session at $168.57, with a gain of 1.37% or 2.28 points. The heightened volatility saw the trading volume jump to 10,00,764 shares. Company has a market cap of $35,771 M.
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.